GeNeuro completes patient recruitment in temelimab Phase 2 multiple sclerosis trial at the Karolinska Institutet’s Academic Specialist Center (ASC)
Geneva, Switzerland, January 11, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced its cash position at December 31, 2020, issued a business update and provided an outlook on its 2021 activities. https://geneuro.ch/data/news/PR-GeNeuro-MS-Study-Enrollment-Complete-EN-021821-VF.pdf